Together, these findings suggest that oxidative stress and inflammation act synergistically to impair both molecular and clinical outcomes in PD, highlighting the therapeutic potential of targeting the SIRT1/Nrf2/NLRP3 pathway to improve quality of life and alleviate fatigue. The gene discussed is SIRT1; the disease is Parkinson disease.